Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Mikhlin v. Oasmia Pharmaceutical AB et al
Case Number:
1:19-cv-04349
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
January 07, 2021
Swedish Biotech Oasmia Settles Investor Claims For $2.4M
A New York federal judge on Wednesday gave preliminary approval to a $2.4 million settlement to end claims from investors that Swedish biotechnology company Oasmia Pharmaceutical AB hid deals it had with two other companies owned by its founder and a former board member.
-
July 30, 2019
Cancer Biotech Oasmia Hid Deals From Investors, Suit Says
Investors for Swedish cancer biotechnology firm Oasmia launched a proposed class action lawsuit in New York federal court Monday, alleging the company actively concealed a number of deals involving entities owned by the biotech's founder and a former board member.